Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule arylsulfonamide, specifically an indole sulfonamide derivative. It is structurally characterized by the presence of a morpholine ring, a pyrrolidine moiety, and an indole core substituted with a sulfonamide group and chlorine at the fifth position. The compound has been identified as "Arylsulfonamide 3b" in chemical databases and is reported to act as an inhibitor of coagulation factor X (also known as Factor Xa), which plays a central role in the blood coagulation cascade. As such, it may have potential applications as an anticoagulant or antithrombotic agent; however, there are no records of clinical development or approval for therapeutic use[6]. No information on its developer or manufacturer was found.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-chloro-n-{(3s)-1-[(2s)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1h-indole-2-sulfonamide.